Deerfield Management Company »

Replimune Group shares owned by Deerfield Management Company

Quarter-by-quarter ownership of Replimune Group (REPL) shares owned by Deerfield Management Company from 13F filings

Historical chart of Deerfield Management Company investment in Replimune Group

Tip: Access up to 7 years of quarterly data

All positions including Replimune Group held by Deerfield Management Company consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Replimune Group by Deerfield Management Company

Quarter filed Position value Share count Share price at filing
2023-12-31 $15M 1.8M 8.43

More positions owned by Deerfield Management Company

Nuvalent Inc-a (NUVL)
Glaukos Corp Note 2.750% 6/1 (Principal)
Viatris (VTRS)
Invitae Corp Debt 4.500% 3/1 (Principal)
Natera Note 2.250% 5/0 (Principal)
Catalyst Pharmaceutical Partners (CPRX)
Centene Corporation (CNC)
Brookdale Sr Living Note 2.000%10/1 (Principal)
Insmed Note 1.750% 1/1 (Principal)
Neurocrine Biosciences (NBIX)
Accolade Note 0.500% 4/0 (Principal)
Oscar Health Cl A (OSCR)
Owens & Minor (OMI)
Adapthealth Corp Common Stock (AHCO)
Springworks Therapeutics (SWTX)

View all positions for Deerfield Management Company

Top funds holding Replimune Group

Baker Bros. Advisors
T. Rowe Price Associates
Fcpm Iii Services B.v.
Redmile Group
Omega Fund Management
Vanguard Group
Goldman Sachs Group
Atlas Venture Life Science Advisors
Deerfield Management Company
Dimensional Fund Advisors
Artal Group
Emerald Advisers
Charles Schwab Investment Management
Vontobel Holding
Jpmorgan Chase & Co

View all funds holding Replimune Group